Prognostic significance of the expressions of metallothionein, glutathione-s-transferase-π, and P-glycoprotein in curatively resected gastric cancer

Oncology (Switzerland)

Volumn 54, Issue 5, 1997, Pages 391-399

  Monden, Naomi ^a   Abe, Shun’ichi ^a   Sutoh, Ichiro ^a   Hishikawa, Yoshitaka ^a   Kinugasa, Shoichi ^a   Nagasue, Naofumi ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Drug resistance; Gastric cancer; Glutathione S transferase ; Metallothionein; P glycoprotein

Indexed keywords

CYCLINE; DOXORUBICIN; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; METALLOTHIONEIN; MITOMYCIN C; PYRIMIDINE; TEGAFUR; TUMOR PROTEIN;

ADULT; ARTICLE; CANCER CELL; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH MUCOSA; SURVIVAL TIME;

ADENOCARCINOMA; AGED; DISEASE-FREE SURVIVAL; FEMALE; GASTRIC MUCOSA; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE TRANSFERASE; HUMANS; MALE; METALLOTHIONEIN; MIDDLE AGED; NEOPLASM STAGING; P-GLYCOPROTEIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0030843282     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227725     Document Type: Article

References (56)

1. Abe S, Shiraishi M, Nagaoka S, Yoshimura H, Dhar KD, Nakamura T: Serosal invasion as the single prognostic indicator in stage III A (TjN~Mo) gastric cancer. Surgery 1991:109: 582-588.
2. Abe S, Yoshimura H, Nagaoka S, Monden N, Kinugasa S, Nagasuc N, Nakamura T: Longterm results of operation for carcinoma of the stomach in T1/Ti stages: Critical evaluation of the concept of early carcinoma of the stomach. J Am Coll Surg 1995;181:389-396.
3. Bcahrs OH, Henson DE, Hutter RVP, Kennedy BJ: Manual for Staging of Cancer, cd 4. Philadelphia. Lippincott. 1992, pp 63-67.
4. Jasani B, Elmes ME: lmmunohistochemical detection of metallothionein. Methods Enzymol 1991:205:95-107.
5. Scheper RJ, Bulle JWM, Brakkee JGP, Quak JJ, van der Schoot E, Balm AJ, Meijer CJ, Broxterman HJ. Kuiper CM. Lankelma J. Pi-ncdo HM: Monoconal antibody JSB-1 detects a highly' conserved epitope on the P-glycoprotein associated with multi-drug-resistancc. Int J Cancer 1988;42:389-394.
6. Waseem NH, Lane DP: Monoclonal antibody analysis ofthc proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form. J Cell Sei 1990:96: 121-129.
7. Hsu SM, Raine L, Fänger H: Use of avidin-bio-tin-peroxidase technique: A comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981:29:577-581.
8. Bacus S, Flowers JL, Press MF, Bacus JW, McCarty KS: The valuation of estrogen receptor in primary breast carcinoma by computer-assisted image analvsis. Am J Clin Pathol 1988: 90:233-239.
9. Bacus SS, Ruby SG, Weinberg DS, Chin D, Ortiz R, Bacus JW: HER-2/neu oncogene expression and proliferation in breast cancers. Am J Pathol 1990;137:103-111.
10. Karin M: Metallothionein: proteins in search of function. Cell 1985;41:9-10.
11. Hamer DH: Metallothionein. Annu Rev Bio-chcm 1986;55:913-951.
12. Endcrsen L, Rugastad HE: Protective function of metallothionein against certain anticancer agents. Experientia 1987;52(suppl):595.
13. Kelley SL, Basu A, Leicher BA, Hacker MP, Hamer DH, Lazo JS: Overexpression of metallothionein confers resistance to anticancer drugs. Science 1988;241:1815-1818.
14. Kasahara K, Fujiwara Y, Nishio K, Ohmori T, Sugimoto Y, Komiva K, Matsuda T, Saijo N: Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res 1991:51:3237-3242.
15. Koropatnick J, Pearson J: Altered cisplatin and cadmium resistance and cell survival in Chinese hamster ovary cells expressing mouse metallothionein. Mol Pharmacol 1993;44:44-50.
16. Lohrer H, Robson T: Ovcrexprcssion of metallothionein in CHO cells and its effect on cell killing by ionizing radiation and alkylating agents. Carcinogenesis 1989:10:2279-2284.
17. Kaina B, Lohrer H, Karin M, Herrlich P: Overexpressed human metallothionein II gene protects Chinese hamster ovary cells from killing by alkylating agents. Proc Natl Acad Sei USA 1990;87:2710-2714.
18. Jacoby W: The glutathione transferase: A group of multifunctional detoxification proteins. Adv Enzymol 1978;46:383-414.
19. Mannervik B: The isoenzyme of glutathione S-transferase. Adv Enzymol 1985;57:357-417.
20. Lewis AD, Forrester LM, Hayes JD, Wareing CJ, Carmichael J, Harris AL, Mooghen M, Wolf CR: Glutathione S-transferase isoenzymes in human tumours and tumour derived cell lines. Br J Cancer 1989;60:327-331.
21. Morow CS, Cowan KH, Goldsmith ME: Structure of the human genomic glutathionc-S-trans-ferase-pi gene. Gene 1989;75:3-11.
22. Shea TC, Kewlley SL, Henner WD: Identification of an anionic form of glutathione transferase present in many human tumors and cell lines. Cancer Res 1988;48:527-533.
23. Hamada H, Tsuruo T: Purification of 170- to 80-Iilodalton membrane glycoprotein associated with multidrug resistance. J Biol Chem 1988;263:1454-1458.
24. Willingham MC, Richert ND, Cornwell MM, Tumo T, Hamada H, Gottcsman MM, Pastan IH: Immunocytochemical localization of P170 at the plasma membrane of multidrug-resistant human cells. J Histochem Cytochem 1987:35: 1451-1456.
25. Chen C, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB: Internal duplication and homology with bacterial transport proteins in the rndrl (P-glycoprotcin) gene from multidrug-resistant human cells. Cell 1986:47:381-389.
26. Moscow JA, Cowan KH: Multidrug resistance. J Natl Cancer Inst 1988;80:14-20.
27. Bradley G, Juranka PF, Ling V: Mechanism of multidrug resistance. Biochim Biophys Acta 1988:948:87-128.
28. Chan HSL, Thorner PS, Haddad G, Ling V: Immunohistochemical detection of P-glycopro-tein: Prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 1990:8:689- 704.
29. Chan HSL, Haddad G, Thorner PG, DeBoer G, Lin YP, Ondrusek N, Yetger H, Ling V: P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 1991:325:1608-1614.
30. Verrell P, Meissonnier F, Fonck Y, Feillel V, Dionet C, Kwiatkowski F, Plagne R, Chassagnc J: Clinical relevance of immunohistochemical detection of multidrug resistance P-glycopro-tein in breast carcinoma. J Natl Cancer Inst 1991:83:111-116.
31. Sincrope FA, Hart J, Brasitus TA, Michelassi F, Lee JJ, Safa AR: Relationship of P-glycopro-tein and carcinoembryonic antigen expression in human colon carcinoma to local invasion. DNA ploidy, and disease relapse. Cancer 1994: 74:2908-2917.
32. Itsubo M, Ishikawa T, Toda G, Tanaka M: Immunohistochemical study of expression and cellular localization of multidrug resistance gene product P-glycoprotcin in primary liver carcinoma. Cancer 1994;73:298-303.
33. Chin JL, Banerjee D, Kadhirn SA, Kontozo-glou TE, Chauvin PJ, Cherian MG: Metallo-thionein in testicular germ cell tumors and drug resistance. Cancer 1993:72:3029-3035.
34. Kondo Y, Kuo SM, Watkins SC, Lazo JS: Metallothionein localization and cisplatin resistance in human hormone-independent prostatic tumor cell lines. Cancer Res 1995:55:474- 477.
35. Bahnson RR, Becich M, Emstoff MS, Sandlow J, Cohen MB, Williams RD: Absence of immunohistochemical mctallothionein staining in bladder tumor specimens predicts response to ncoadjuvant cisplatin. methotrexate and vinblastine chemotherapy. J Urol 1994; 152:2272-2275.
36. Twentyman PR, Wright KA, Mistrv P, Kelland LR, Murrrer BA: Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin. Cancer Res 1992;52:5674-5680.
37. Nakagawa K, Saijo N, Tsuchida S, Sakai M, Tsunokawa Y, Yokota J, Muramatsu M, Sato K. Terada M. Tew KD: Glutathionc-S-trans-ferase it as a determinant of drug resistance in transfectant cell lines. J Biol Client 1990:265: 4296-4301.
38. Moscow JA, Townsend AJ, Cowan KH: Elevation of pi-class glutathione S-transferase activity in human breast cancer cells by transfection of the GST-it gene and its elTcct on sensitivity to toxins. Mol Pharmacol 1989:36:22-28.
39. Okuyama T, Maehara Y, Endo K, Baba H, Adachi Y, Kuwano M, Sugimachi K: Expression of glutathione S-transferasc-pi and sensitivity of human gastric cancer cells to cisplatin. Cancer 1994:74:1230-1236.
40. Heegaard S, Sommer HM, Broholm H, Broendstrup O: Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis. Cancer 1995:76:1809-1813.
41. Teixeira CR, Tanaka S, Ilaruma K, Yoshihara M, Sumii K, Kajiyama G: Proliferating cell nuclear antigen expression at the invasive tumor margin predicts malignant potential of colorectal carcinomas. Cancer 1994:73:575- 579.
42. Hickey K, Grehan D, Reid IM, O'Briain S, Walsh TN, Hennessy TPJ: Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal sqamous cell carcinoma to chemoradio-thcrapy. Cancer 1994;74:1693-1698.
43. Bravo R, Frank R, Blundell PA, Bravo HM: Cyclin/PCNA is the auxiliary protein of DNA polymerase-5. Nature 1987;326:515-517.
44. Hall PA, Levinson DA, Woods AL, Yu CC, Kellock DB, Watkins JA, Barnes DM, Gillett CE, Camplejohn R, Dover R: Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: An index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990:162:285-294.
45. Bravo R, Bravo HM: Existence of the population of cyclin/proliferating cell nuclear antigen during the cell cycle: Association with DNA replication sites. J Cell Biol 1987:105:1549-1554.
46. Danova M, Riccardi A, Giordano M, Girino M, Mazzini G, Dezza L, Ascari E: Cell cycle-related proteins: A flow cytometric study in human tumors. Biol Cell 1988;64:23-28.
47. Jain S, Filipc MI, Hall PA, Waseent N, Lane DP, Levison DA: Prognostic value of proliferating cell nuclear antigen in gastric carcinoma. J Clin Pathol 1991:44:655-659.
48. Macda K, Chung YS, Takatsuka S, Ogawa Y, Onoda N, Sawada T, Kato Y, Nitta A, Arimoto Y, Kondo Y, Sowa M: T untor angiogenesis and tumour cell proliferation as prognostic indicators in gastric carcinoma. Br J Cancer 1995,72: 319-323.
49. Yonemura Y, Kimura H, Fushida S, Tugawa K, Nakai Y, Kaji M, Fonseca L, Yamaguchi A, Miyazaki I: Analysis of proliferative activity using antiprolifcrating cell nuclear antigen antibody in gastric cancer tissue specimens obtained by endoscopic biopsy. Cancer 1993:71: 2448-2453.
50. Maeda K, Chung YS, Onoda N, Ogawa M, Kato Y, Nitta A, Arimoto Y, Kondo Y, Araka-wa T, Sowa M: Association of tumor cell proliferation with lymph node metastasis in early gastric cancer. Oncology 1996;53:1-5.
51. Filipe ML Mendes R, Lane DP, Morris RW: Assessment of proliferating cell nuclear antigen expression in precursor stages of gastric carcinoma using the PC10 antibody to PCNA. His-topathology 1993:22:349-354.
52. Hcppner GH: Tumor heterogeneity. Cancer Res 1984:44:2259-2265.
53. Nowell PC: Mechanisms of tumor progression. Cancer Res 1986:46:2203-2207.
54. Schnipper LE: Clinical implications of tumorcell heterogeneity. N Engl J Med 1986:314: 1423-1431.
55. Fujii H, Tanigawa N, Muraoka R, Shimomat-suya T, Tanaka T: Clinical significance of multidrug resistance and P-glycoprotein expression in patients with gastric carcinoma. J Surg Oncol 1995;58:63-69.
56. Bradley G, Ling V: P-glycoprotein. multidrug resistance and tumor progression. Cancer Metastasis Rev 1994;13:223-233.